The science of central hearing loss - and how we reverse it.

Watch Overview

Identifying the pervasive hearing problem without an established treatment

In a crowded restaurant, conversations blur for hundreds of millions of people. The cause isn't the ears — it's the brainstem. A circuit in the medial nucleus of the trapezoid body handles the microsecond timing needed to separate signal from noise. This speed and precision comes from thick myelin wrapping neural axons in this circuit. With age, the myelin insulating those neurons thins, and following a single voice in a noisy room becomes impossible.

Scientists call this central hearing loss, or "cocktail party syndrome." Audiologists will often refer to it as hidden hearing loss or a form of Central Auditory Processing Disorder (CAPD). Regardless of the name, it impacts one third of people over the age of 40, and half of people over 65 — and hearing aids make it worse by amplifying noise into an already overloaded system.

To make matters more serious, the Lancet Commission identifies hearing loss as the largest modifiable risk factor for dementia, with lifetime risk approximately doubled for those who struggle in noise.

Meet LOOT: The first therapy targeting the neurological root cause.

Localized Oligodendrocyte Optimization Therapy (LOOT) is a 30-day combination of targeted audio stimulation with a repurposed, previously FDA-approved, oral medication. Together, they prompt the brain to repair the myelin sheaths in the auditory brainstem that have worn down with age.

Reduced

Myelin Integrity

Optimized

With LOOT

How LOOT Works

Targeted audio therapy

Patients listen to precisely engineered soundscapes through consumer-grade headphones. The audio is designed to drive the specific brainstem circuit that has lost myelin, signaling to local oligodendrocytes that more insulation is needed. However, sound alone did not heal the circuit in preclinical studies, as the stem cells responsible for making myelinating cells are not behaving normally in CAPD.

Oral clemastine fumarate

Clemastine is a decades-old, FDA-approved antihistamine with a well-characterized safety profile. At a higher dosage, evidence is mounting that it also promotes oligodendrocyte precursor cell (OPC) differentiation into mature Oligodendrocytes: the cells that lay down new myelin. On its own, it does nothing for hearing in preclinical investigations. Paired with the audio stimulus, preclinical studies suggest it primes the OPCs to enable the brain's natural repair response in exactly the right place.

Neither component works alone. The combination is what's patented, and it's what produced ~90% reversal of age-related central hearing loss in our preclinical animal studies.

30 years of research. One causal mechanism. ~90% reversal in animals.

1996

Dr. Achim Klug begins what would be his decades long career studying the auditory brain, by focusing on nature's most extreme design: bat echolocation

2009

Klug Lab opens at the University of Colorado to continue his basic science investigations of the auditory brain and how it localizes sounds in space

2014

Klug Lab's investigations lead to the surprising discovery of deficits in brain stem myelination checkered with hearing in noise difficulties

2019

A $7M NIH grant is awarded to further investigate the demyelination hypothesis

2023

Neurosurgical animal studies and computational models confirm the root cause; treatment shows a 1.5 effect size in preclinical experiments

2025

First patent filed, company formed, two additional NIH grants scored 3rd & 8th percentile, FDA clears IND 175835

2026

FDA Phase II clinical trial begins enrollment at CU Anschutz; $6M NIH grant for basic science; second patent filed

Are you losing conversations in noisy rooms?

Phase II volunteer enrollment is open at CU Anschutz Medical Campus.

Are you a Montana ENT or audiologist?

Be among the first clinics in the country to offer LOOT